Loading...
XASESTXS
Market cap198mUSD
Dec 24, Last price  
2.34USD
1D
-0.43%
1Q
17.59%
Jan 2017
260.06%
Name

Stereotaxis Inc

Chart & Performance

D1W1MN
XASE:STXS chart
P/E
P/S
7.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
9.15%
Rev. gr., 5y
-1.82%
Revenues
27m
-4.89%
18,816,86015,026,39027,191,70639,298,80940,365,17351,149,55554,051,23741,987,43246,562,43438,031,08135,011,27637,674,52432,164,11631,144,10029,346,61728,902,55026,630,03535,020,86228,147,00026,771,000
Net income
-21m
L+8.16%
-27,257,469-43,557,835-45,719,770-48,121,514-43,885,974-27,494,457-19,923,487-32,031,175-9,238,427-68,757,589-5,202,441-7,352,775-5,286,720-5,887,410116,756-4,232,973-6,452,892-8,437,150-19,151,000-20,713,000
CFO
-9m
L+8.60%
-31,813,870-40,986,183-38,982,881-35,713,494-28,654,503-22,308,663-18,909,745-31,569,278-12,117,658-6,331,644-9,092,143-2,528,501-6,562,754-4,674,567-2,546,582-4,616,680-3,511,772-2,945,911-8,415,000-9,139,000
Earnings
Mar 03, 2025

Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
IPO date
Aug 12, 2004
Employees
130
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
26,771
-4.89%
28,147
-19.63%
35,021
31.51%
Cost of revenue
48,610
46,923
47,909
Unusual Expense (Income)
NOPBT
(21,839)
(18,776)
(12,888)
NOPBT Margin
Operating Taxes
859
(2,278)
Tax Rate
NOPAT
(21,839)
(19,635)
(10,610)
Net income
(20,713)
8.16%
(19,151)
126.98%
(8,437)
30.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
81
220
547
BB yield
-0.06%
-0.14%
-0.12%
Debt
Debt current
856
373
268
Long-term debt
10,552
11,349
11,953
Deferred revenue
1,637
1,654
2,238
Other long-term liabilities
43
51
219
Net debt
(8,410)
(17,452)
(27,469)
Cash flow
Cash from operating activities
(9,139)
(8,415)
(2,946)
CAPEX
(366)
(2,378)
(1,397)
Cash from investing activities
19,765
(22,094)
(1,397)
Cash from financing activities
81
220
547
FCF
(20,978)
(20,856)
(17,869)
Balance
Cash
19,818
28,430
38,739
Long term investments
744
952
Excess cash
18,479
27,767
37,939
Stockholders' equity
(532,022)
(511,303)
(493,011)
Invested Capital
560,923
550,751
540,825
ROIC
ROCE
EV
Common stock shares outstanding
80,702
76,061
75,558
Price
1.75
-15.46%
2.07
-66.61%
6.20
21.81%
Market cap
141,229
-10.30%
157,447
-66.39%
468,461
26.52%
EV
138,396
145,584
446,581
EBITDA
(21,244)
(18,347)
(12,783)
EV/EBITDA
Interest
484
10,071
Interest/NOPBT